HONG KONG – China's Zhejiang Hisun Pharmaceutical Co. Ltd. said results of two key phase III trials for HS-25, a cholesterol absorption inhibitor that targets hyperlipoproteinemia, showed both met the standard 12-week descent rate of low-density lipoprotein cholesterol (LDL-C), while adverse drug reactions were minor. In the next one to two months, the company is expected to apply to the National Medical Products Administration (NMPA), China's FDA, for marketing clearance.